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Background: Sclerotherapy has been shown to be an effective and increasingly popular therapeutic strategy for the
treatment of varicose veins. However, recent reports of serious side effects, including cerebrovascular accidents (CVA)
and transient ischemic attacks (TIA), as well as speech and visual disturbances, have caused serious concern regarding its
use. This review evaluated the reported incidences of neurological side effects associated with the use of sclerotherapy.
Methods: A systematic search of the data bases MEDLINE, OVID Embase, and Google Scholar was undertaken by two
independent reviewers. Articles reporting neurological side effects in humans following foam and liquid sclerotherapy
were included; animal studies, laboratory studies, and review articles were excluded. Additional references were also
obtained using the related articles function.
Results: The search yielded 1023 articles, of which 41 studies were found to meet the inclusion criteria. A total of 10,819
patients undergoing sclerotherapy were reviewed. There were 12 case reports of CVA with confirmatory brain imaging
and nine reports of TIA. There were 97 (0.90%) reports of neurological events overall, including TIA, visual and speech
disturbances, and 29 cases of reported migraine (0.27%). Symptoms occurred at times ranging from minutes to several
days following sclerotherapy. Eleven patients with TIA or CVA were found to have a right to left cardiac shunt, usually
a patent foramen ovale.
Conclusions:Neurological side effects following sclerotherapy are a rare occurrence; however, CVA associated with the use
of sclerotherapy is clearly documented. The pathologic mechanisms resulting in CVA are likely to be different to those
leading to migraine and visual disturbances; however, care should be exercised in patient selection, particularly in those
with known cardiac defects. ( J Vasc Surg 2012;55:243-51.)
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MChronic venous insufficiency poses a huge burden to
patients’ quality of life and thus, to the economic stand-
point of healthcare systems, which have helped to drive the
impetus to explore effective and safe treatment strategies.
In recent years, the increasing popularity of minimally
invasive techniques has resulted in a shift away from tradi-
tional surgery and procedures performed under general
anesthesia, toward an out-patient based approach.1,2 The
concept of treating varicose veins on an outpatient basis
requiring little expense has made sclerotherapy an attractive
option, in comparison to other invasive or minimally inva-
sive techniques.3 Although early attempts to treat varicose
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doi:10.1016/j.jvs.2011.05.093eins with sclerosing agents were fraught with complica-
ions, predominantly consisting of infections, phlebitis, and
angrene, such that cessation of their use was advised by a
anel of experts at a surgical congress in Lyon in the 1800s,
he development of newer sclerosants and techniques to
mprove efficacy has led to a wide acceptance of foam
clerotherapy, which is now considered by many to be a
ighly successful treatment strategy with minimal side ef-
ects.4 Foam sclerotherapy is used to treat truncal incom-
etence, perforating veins, and primary and secondary var-
cosities as well as reticular and spider veins. It is also used in
ombination with traditional surgery or endovenous ther-
al ablation. However, recently highlighted serious sys-
emic adverse events, including deep venous thrombosis,
ulmonary embolism, and, particularly, neurological events
uch as transient ischemic attacks (TIA) and cerebrovascu-
ar accidents (CVA) have slowed the fervor that was initially
bserved.5,6 In this study, we present a review of the
iterature of the various neurological complications ob-
erved following the use of sclerotherapy.
ETHODS
Search strategy. An electronic search was carried out
sing PubMed, OVID Embase, and Google Scholar to
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January 2012244 Sarvananthan et alidentify all studies concerned with the use of sclerotherapy
for the treatment of varicose veins that reported on neuro-
logical complications. The following search terms were
used: “vein and sclerotherapy and (TIA or speech or stroke
or CVA or migraine or headache or visual or complica-
tion).” Based on the title and abstract of the publication,
articles containing clinical data on the neurological compli-
cations of sclerotherapy were reviewed in detail. The “re-
lated articles’’ function was utilized to broaden the search,
and all abstracts, studies, and citations were reviewed for
each selected publication. References of the articles acquired
were also searched manually. No language restrictions were
made. The latest date for this search was January 2011.
Inclusion and exclusion criteria. Any article that re-
ported on neurological complications of sclerotherapy for
treatment of varicose veins in humans was included. Labo-
ratory and animal studies were excluded. Systematic
reviews, questionnaires, and registries reporting on sclero-
therapy were excluded to avoid duplication of data.
Data extraction and quality assessment. Two inde-
pendent reviewers (A.S., T.S.) assessed the data from each
accepted paper and extracted the following information:
author, year of publication, type of publication, number of
Fig. QUORUM diagram detacases treated, the type of sclerosant used, neurological iomplications observed, and the presence of any detected
ardiac abnormalities. The reported neurological complica-
ions were categorized as CVA, TIA, visual disturbances, or
peech disturbances. CVA were diagnosed based on the
resence of confirmatory cerebral imaging. Episodes were
lassified as TIA if they had been reported as TIA in the
riginal publication; symptoms were otherwise reported as
isual or speech disturbances. The numbers of patients
eporting migraine or headache were also reported, al-
hough the authors acknowledge these may not necessarily
epresent neurological complications; the criteria used to
ifferentiate between headache, migraine with aura, and
isual disturbances is likely to have been different in differ-
nt studies and for this reason all are included. Any discrep-
ncy between the two independent reviewers was resolved
ollowing discussion with a third party.
ESULTS
The search yielded 1023 articles, of which 41 articles
et the inclusion criteria and were subsequently included.
f these articles, there were 15 case reports, one correspon-
ence, two published abstracts, four retrospective studies,
4 prospective studies, and five prospective randomized stud-
the systematic search strategy.es. A summary of the papers included is detailed in the Figure.
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Volume 55, Number 1 Sarvananthan et al 245This gave a total of 10,819 patients who underwent
sclerotherapy with either liquid or foam sclerosants. Sodi-
um-tetradecyl sulfate (STS) was used in 5990 cases, poly-
docanol (POL) in 3999 cases, chromated glycerin (CRO)
in 52 cases, and sodium morrhuate in one case.
Case reports. Themajority of neurological side effects
defined as TIA or CVA were reported as case reports or
small case series (Table I). Nine patients were reported to
have had a TIA, three of which were reported as case
reports; however, the authors are unable to state whether or
not all of these diagnoses were confirmed by a neurologist.
CVA was reported to have occurred in 12 patients, all of
which were reported as case reports. Confirmatory cerebral
imaging of the presence of CVA was confirmed either by
computed tomography imaging (CT) in four patients7-10
or magnetic resonance imaging (MRI) in six patients.11-14
One patient had normal MRI imaging but, due to persis-
tent symptoms for 2 days, was classified as having had a
CVA,15 and one patient had thrombus in the right middle
cerebral artery on autopsy.16 The earliest case report found
was in 1947, published in the British Medical Journal, of
transient hemiplegia and speech disturbance in a 32-year-
old female after the injection of sodium morrhuate,16 and
in 1951, a 62-year-old female patient who died shortly after
injection of sodium morrhuate into varices16 was found to
have evidence of intracranial hemorrhage and thrombus in
the middle cerebral artery at postmortem. The other cases
included four left middle cerebral artery (MCA) territory
infarcts, one right MCA infarct, two right-sided cerebellar
infarcts, one right frontal infarct, and two cases of air
emboli in the MCA. The timing of the onset of symptoms
was highly variable. In eight cases, symptoms occurred
within minutes of treatment,7,8,12,13,16,17 in three cases
this occurred at 1 to 4 hours,14,15,18 two cases reported
symptoms the following day within 24 hours,11,13 and the
remaining cases were at 2 days, 3 days, and 5 days following
treatments.9,10,13 In two cases, residual weakness was ob-
served at the time of discharge from hospital, and there was
one reported fatality in the case of the patient who suffered
a hemorrhagic stroke.16 However, in the majority of cases,
symptoms completely resolved prior to discharge from the
hospital. In 11 of the 16 cases of TIA or CVA, the patients
were confirmed to have a patent foramen ovale (PFO) on
echocardiography or transesophageal imaging; in three
cases no cardiac defects were found; and in the remaining
three cases, results of cardiac investigations are not men-
tioned. There was one reported case of an episode of
transient visual and speech disturbance, not thought to be
due to a TIA that occurred in a patient with a PFO. In seven
cases (37%), liquid sclerosants were used resulting in one
migraine, four CVAs, and two TIAs. The remaining 12
(63%) were following foam sclerotherapy and included
eight CVAs, one TIA, and one migraine.
Cohort studies and randomized trials. The remain-
ing 26 articles included prospective or retrospective studies
and randomized trials and evaluated 10,801patients. There
were six additional cases (0.06%) of TIA or amaurosis fugax
reported, one of whom had a proven PFO. No cases of wVA were reported. Visual disturbances not considered to
e a TIA or CVA were reported to have occurred in 84 of
0,801 (0.78%) patients within the cohort studies. A total
f 357 treatment sessions using liquid sclerosants were
dentified; however, in all the mentioned studies, this was
ompared with foam sclerosants. In two studies, the au-
hors specify that the visual disturbances occurred follow-
ng the administration of foam rather than liquid.19,20 In
he remaining two studies, there were six episodes of tran-
ient visual disturbances where the treatment preparation
as not specified, and therefore may have occurred follow-
ng liquid sclerosants. There were eight cases of headache
ollowing liquid sclerosants.21,22 One patient reported an
solated speech disturbance, and one study reported on six
ases of visual disturbances, paresthesia headache, and mi-
raine; however, numbers were unspecified (Table II).23
n additional 76 patients in total (0.70%) reported head-
ches, and 29 (0.27%) reported migraine with aura (Table
I). The overall incidence of neurological complications,
efined as including TIA, CVA, and/or speech, visual, or
otor disturbances but not including migraine, calculated
rom the combined data from the cohort studies and ran-
omized trials was 97 (0.90%). Cardiac defects, including
FO, were reported in three patients with migraine; how-
ver, cardiac investigations were not carried out in all
atients. Techniques used to create foam varied widely, but
he Tessari24 technique appeared to be the most frequently
sed (Table II). Concentrations of sclerosant used fre-
uently depended on the type of vein treated and the
clerosant utilized, but varied from 0.25% to 5%. The
olumes of sclerosant used also varied significantly, and
requently depended on the size and nature of the veins
reated; however, in the majority of studies, 20 mL of
oam per patient was used. In five studies, more than 20mL
as frequently used; however, no association between the
olumes of foam used and the reporting of neurological
ide effects was identified (Table II). Air was the most
requently used gas; however, CO2 was used in three stud-
es, and O2 was used in one study. The most frequently
sed ratio of gas to sclerosant mixture was 1:4; however,
atios ranged from 1:2 to 1:8. No association between the
as used or the ratio of gas and sclerosant and the number
r type of neurological side effects was observed (Table II).
ISCUSSION
The findings of this systematic review highlight that
erious neurological complications following foam sclero-
herapy are rare, particularly when carried out by trained
linicians in a controlled environment. However, the oc-
urrence of CVA and TIA is well-documented following
clerotherapy and therefore raises understandable concern.
he majority of these incidences are published as case
eports with confirmatory evidence of cerebral ischemia,
lthough the majority of patients had no residual deficit
hen discharged from hospital. The first recorded inci-
ence of CVA following sclerotherapy appears to have
ccurred in 1951 and resulted in the death of a 41-year-old
oman. Intracranial hemorrhagic and thrombus in the
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examination, the reasons behind which are unclear. The
authors of the original paper suggested that the death was
likely to have occurred as a result of anaphylaxis; they were
unable to explain the intracranial thrombus and hemor-
rhage. The precise mechanism behind the occurrence of
symptoms is poorly understood, and several different etiol-
ogies have been suggested. The authors acknowledge that
the techniques used for the injection of sodium morrhate
into varices in the 1940s and 1950s were considerably
different from techniques used in sclerotherapy today. In
the majority of patients with CVA or TIA, a PFO or other
right to left cardiac shunt has been identified, and the
majority of authors hypothesize that symptoms occur as a
consequence of particles of sclerosant arriving in the cere-
bral circulation through a right to left cardiac shunt. Evi-
dence for the theory includes the demonstration of bubbles
on transcranial Doppler (TCD); however, foam bubbles in
the middle cerebral artery have been observed on TCD in
the absence of neurological complications25 in up to 42% of
patients undergoing foam sclerotherapy.26 Other proposed
mechanisms include the fact that symptoms occur as a
result of air embolus, and confirmatory MRI images of air
bubbles in the cerebral circulation of symptomatic patients
suffering CVA have been reported.12,13 Similar neurologi-
cal symptoms have also been observed in divers after sur-
facing, whereby air bubbles have been shown to cause
transient neurological symptoms.27 It has also been sug-
gested that an inflammatory reaction to the sclerosant may
cause vasospasm resulting in symptoms.28
Liquid sclerotherapy was the first of its kind to be
utilized, but further technical refinement has led to the
development of “foam,” which was formally published by
Orbach.29 Foam is a combination of sclerosant and gas and
Table I. Overview of case report studies reporting neurolo
First author Year
Type of
study
Total
patients
Type of
vein
Foam
used
Benigni33 2003 CR 1 RV 1
Bush7 2008 CR 2 P, RV, T 2
Drai17 1994 CR 1 V 0
Forlee8 2006 CR 1 GSV 1
Gardner34 1947 CR 1 V 0
Hahn1 2010 CR 1 SSV 1
Hanish10 2004 CR 1 R, T 0
Hartmann18 2009 CR 1 GSV, SSV 1
Kas11 2000 CR 1 T 1
Kunzlberger28 2006 CR 1 T 0
Leslie-Mazwi12 2009 CR 1 U 1
Ma13 2011 CR 3 V 3
Peller16 1951 CR 1 V 0
Picard14 2010 CR 1 GSV 1
Van der Plas15 1994 CR 1 GSV, P 0
AASV, Anterior accessory saphenous vein;ASD, atrial septal defect;CR, case
NA, not applicable; P, perforating vein; PFO, patent foramen ovale; POL, p
sulphate; T, telangiectasia; TIA, transient ischemic attack; U, unknown/unhas been favored over liquid sclerotherapy due to its pro- gonged contact with the vein intima by its ability to displace
lood from the treated vein and thus requires reduced
mounts of sclerosant for treatment.30 It has been sug-
ested that neurological side effects appear to be more
ommonwith the use of foam,31 with a median rate of 1.4%
uoted in a previous systematic review.6 However, the
uthors report four cases of CVA and seven cases of TIA
ollowing the use of liquid sclerosants in this review. This
ncluded two case reports of neurological events of likely
troke and TIA,16,32 which were originally reported as
naphylactic reactions to sodium morrhate. Therefore,
here may be a number of neurological events that were
ncorrectly attributed to anaphylactic reactions following
iquid sclerosants that have gone unnoticed.
It has been suggested that the method for foam cre-
tion may also be an influencing factor for the development
f neurological symptoms due to the varying size of bub-
les produced. The Monfreux method generates foam via
he use of a glass syringe that contains liquid sclerosing
olution. The outlet of the syringe is sealed and the piston
s pulled back drawing air into the syringe through the gap
etween the syringe body and the piston, creating a fluid
oam with reasonably large bubbles.24
This method has been proposed to have higher rates of
ide effects such as dizziness and states of confusion,25
hought to be due to the creation of larger air bubbles,
lthough the true nature of these symptoms is question-
ble. Due to the fact that not all studies published details of
he methods used to create foam, and the relatively small
umber of neurological side effects that were observed, the
uthors were unable to conclude whether the method of
oam creation had any effect on the incidence of neurolog-
cal side effects. However, the majority of the studies in-
luded utilized the Tessari technique, which is distin-
l complications following foam sclerotherapy
id
Technique Volume
Concentration of
sclerosant (%)
Ratio of
liquid:air
U 2 mL 0.2 U
Tessari 2-10 mL 2 U
U U U U
Tessari 20 mL 0.5 —
NA 0.75 mL 5 —
Tessari 3 mL 1 —
U 0.5 mL 0.5 NA
DSS 9 mL 3 1:4
U 1 mL U U
NA 2 mL 1 NA
Benigni-Sadoun U U U
Tessari 4-16 mL 1.5-3 1:3
NA 2 mL 5 —
Tessari 4 mL 0.5 1:4
NA 2 mL
1 mL
3
1
NA
;CVA, cerebrovascular accident;GSV, great saphenous vein;mL, milliliters;
canol; R, reticular vein; SSV, small saphenous vein; STS, sodium-tetradecyl
ed; V, varices/varicosities/tributaries.gica
Liqu
used
0
0
1
0
1
0
1
0
1
1
0
0
1
0
1
reportuished by creating a mixture of fine-bubbled sclerosant in
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is flushed back and forth between the two syringes via a
three-way tap, usually in the ratio of one part sclerosant to
four parts air.26 This technique is believed to contain
compact, smaller diameter air bubbles within the foam,
providing further evidence that additional factors are likely
to be involved. The volumes of foam sclerosant used have
also been called into question. Many have suggested that
the use of large amounts of foam, such as the 20mL used in
the case of ischemic stroke reported by Forlee et al,8 is
unsafe. However, this review highlighted other cases that
also reported the subsequent development of CVA when
using10mL of foam7,14,15 and thus, the degree to which
the volume of sclerosant injected contributes to the devel-
opment of neurological side effects is questionable. How-
ever, the majority of studies included in this review appear
to have used 20 mL of foam per patient.
It is likely that the pathologic mechanism resulting in
CVA is different than that occurring in patients reporting
transient visual, speech, and motor disturbances and symp-
toms of migraine, and it is likely that the majority of the
neurological side effects seen are unrelated to true CVAs,
which are very rare. The majority of symptoms occurred
within minutes to hours after the injection of sclerosant;
however, there are cases of symptoms occurring up to 5
days afterward.9 It is highly implausible that this could have
been caused by an air or sclerosant particle in the cerebral
circulation, and the authors suggest it may have been
caused by a paradoxical venous thromboembolism and
although a PFO was demonstrated in this case,9 no evi-
dence of deep vein thrombosis was found. Indeed, there
has also been a case report of a TIA following phlebectomy,
which may have been a coincidental association.27 Patients
Table I. Continued
Type of gas Sclerosant
Air O2 CO2 STS POL CG Migraine
U U U 0 1 0 1
2 0 0 2 0 0 0
U U U U U U 0
1 0 0 0 1 0 0
NA NA N Sodium morrhuate 0
1 0 0 0 1 0 0
U U U 0 1 0 0
1 0 0 0 1 0 0
U U U 0 0 1 0
NA NA NA 0 1 0 1
U U U 1 0 0 0
3 0 0 3 0 0 0
NA NA NA Sodium morrhuate 0
1 0 0 0 1 0 0
NA NA NA 0 0 0 0known to suffer from migraine with aura appear to be at vreater risk of developing visual disturbances,28 and it has
een suggested that these visual disturbances correspond to
igraines with aura.29 An association between migraines
ith aura and PFO has been quoted by many observational
tudies and may offer a plausible explanation for the occur-
ence of visual disturbances after sclerotherapy. This has
een strengthened by research published by Raymond-
artimbeau, whereby 71.4% of patients reporting visual
isturbances, migraines with aura, or chest tightness fol-
owing foam sclerotherapy were found to have PFO.30 It
as been suggested that cytokines, such as endothelin re-
eased by the action of foam sclerosants acting on the
ndothelium, reach the cerebral arterial circulation through
ight to left cardiac or intrapulmonary shunts. Endothelin
as been shown to initiate one of the pathways leading to
igraine with aura. Support for this theory is provided by
eported incidences of migraine with aura reported follow-
ng angiographic studies.29 It is hypothesized that foam
ubbles passing through a PFO may induce endothelin
elease, which quickly reaches the cerebral cortex, leading
o cortical spreading depression, a depolarizing waveform
ccurring in the cerebral cortex, and shown to be associated
ith migraine with aura, including visual, speech, and
otor disturbances.31 Levels of endothelin measured in
ats following foam sclerotherapy appear to be significantly
igher than in those who have been treated with liquid
clerosants32 in the minutes following the procedure,
hich may provide an explanation as to why neurological
ymptoms appear to occur more frequently following foam
clerotherapy. Generally, the pressure gradient between the
ight and the left atrium is small in most patients with
FOs, but the incidence of shunting can be increased when
he pressure in the right atrium is raised, such as during
rological symptoms/disturbances
Cardiac
defectdache Visual Speech TIA CVA
0 0 0 0 0 U
0 0 0 1 1 ASD  U
0 0 1 1 0 PFO
0 0 0 0 1 PFO
0 1 1 1 0 U
0 0 0 0 1 PFO
0 0 1 0 1 PFO
0 1 1 0 0 PFO
0 0 1 0 1 PFO
0 0 0 0 0 0
0 0 0 0 1 0
0 0 0 0 3 3x PFO
0 0 0 0 1 Not detected
0 0 0 0 1 PFO
0 0 0 0 1 UNeu
Heaalsalva maneuvers. Therefore, it has been suggested that
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or compression stockings and remaining supine following
injection of foam33 for approximately 5 minutes may re-
duce the risk. In the majority of studies evaluated in this
review, details of such activities are infrequently published,
making it difficult for the authors to comment as to
whether this contributed to any of the side effects reported.
Table II. Overview of cohort and randomized studies rep
sclerotherapy
First Author Year
Type of
study
Total
patients Type of vein
F
Bergan35 2006 PR 293 GSV, P, V
Bhogal36 2008 PA 112 —
Bradbury37 2010 PR 977 GSV, SSV,
AASV
125
Cabrera38 2004 RR 116 GSV, SSV, P
Cabrera39 2001 RR 783 GSV  V
Cavezzi40 2002 PR 194 75 V, 15 R, 11
AASV, 33
SSV, 43 GSV,
17 P
Ceulen41 2008 C 35 U
Chapman42 2009 PR 146 146 GSV
Darke43 2006 PR 181 115 GSV, 28
SSV, 77 other
Demagny19 2002 PRT 254 GVS  V 200
Frullini44 2002 RR 453 337 large veins
116 small
varicosities
Frullini45 2000 RR U GSV, SSV, V 595
Gillet46 2010 PR 20 GSV n  7, SSV
n  2, AASV
n  4, V n 
10, R n  5,
P n  1
Gillet47 2009 PR 1025 818 GSV
207 SSV
1
Kern20 2004 PRT 150 150 RV  SV
Morrison48 2008 PR 177 GSV, SSV, V
Myers49 2007 PR 489 453 GSV
174 SSV
Neuhardt23 2008 PA 75 U
Ouvry21 2008 PRT 95 95 GSV
Park50 2009 PR 312 437 GSV/SSV
Raymond-
Martimbeau51
2009 PR 3259 GSV, SSV, V 3
Reich-
Schupke52
2010 PR 76 V 110
Smith53 2006 PR 808 1109 GSV 
SSV
Tessari54 2001 PR 77 24 GSV/SSV
30 V
23 RV/SV
Wright22 2006 PRT 562 GSV, SSV
Yamaki55 2009 PRT 107 107 GSV
AASV, Anterior accessory saphenous vein;ASD, atrial septal defect;C, corres
saphenous vein;mL, milliliters;NA, not applicable; P, perforating vein; PA, p
cohort study; PRT, prospective randomized trial;R, reticular vein;RR, retro
TIA, transient ischemic attack; U, unknown/unspecified; V, varices/varicoFurther studies to support this hypothesis are awaited, tlthough it is important to note the contrast between the
elatively high prevalence of PFO in general population (up
o 25%)34 and the exceedingly low incidence of neurolog-
cal complications after foam sclerotherapy. It is, therefore,
ighly likely that additional factors are involved, and, in
iew of these data, the authors feel unable to justify the
outine investigation of all patients for a cardiac defect prior
g neurological complications following foam
Liquid
used Technique
Volume of foam
(cm3)
Concentration
of sclerosant
(%)
0 Tessari 5-10 mL 1-3
0 U 10-17 mL U
s 0 Tessari 4-8 mL 1-3
0 U 1-30 mL 0.27-1
0 U 10-20 mL 0.25-3
0 Tessari 2.9 mL 0.2
0 U 5 mL 1
0 Tessari 7.3 mL 3
0 Tessari 14 mL 1
s 200 veins U 2 mL 1.5-3
196 257 Monfreux
196 Tessari
U U
s 0 Frullini U U
0 DSS 
Sterivein
device
5.60  2.77 mL 0.5-3
0 Tessari/DSS 4.5 mL 0.5-3
99 Monfreux 10 mL 100 CRO
0.25 POL
0 Tessari 6-57 mL 1
U Tessari 3-40 mL 0.6-3 foam
3 liquid
0 Tessari 4-35 mL 1-3
48 DSS 2-2.5 mL 3
0 Tessari 2-13 mL 3
0 Raymond-
Martimbeau
0.5-8 mL 0.5-3
0 Tessari 1-2 mL 0.5
0 Tessari 20 mL 1-3 STD
1 POL
0 Tessari 1-8 mL 0.1-3
10 U 30 mL 1
9.8 mL 0.5-3
0 Tessari 0.7-4 mL 1-3
nce;CRO, chromated glycerin;CVA, cerebrovascular accident;GSV, great
ed abstract; PFO, patent foramen ovale; POL, polydocanol; PR, prospective
e cohort study; SSV, small saphenous vein; STS, sodium-tetradecyl sulphate;
tributaries.ortin
oam
used
293
112
2 leg
116
783
194
35
146
181
vein
257
vein
20
025
51
177
100
47
312
259
legs
808
77
552
107
ponde
ublisho sclerotherapy, which would be impractical.
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Volume 55, Number 1 Sarvananthan et al 249It has also been suggested that the solubility of the
gas used to create the foam may have an effect on the
complications observed. The replacement of air mixture,
containing high percentages of relatively insoluble nitro-
gen with carbon dioxide, which is highly soluble, has
been shown to reduce side effects such as dizziness and
chest tightness, but no statistically significant reduction
was noted in the occurrence of visual disturbances or
Table II. Continued
Ratio of
liquid:
air
Type of gas Sclerosant
Air O2 CO2 STS POL CG Mig
1:4 293 0 0 0 34 0
U U — U U
1:4 977 0 0 977 0 0
U 0 0 116 0 116 0
U 783 0 0 Lauromacrogol 400
1:4/5 194 0 0 194 0 0
1:4 35 0 0 0 35 0
1:3 146 0 0 146 0 0
1:3 181 0 0 0 181 0
1:4 200 — 0 400 0 0
U 453 0 0 363 90 0
1:2 595 U U 387 208 0
1:4-1:8 20 0 0 1 19 0 1
1:1-1:5 953 72 0 94 931 0
1:4 150 0 0 0 99 51
1:4 49 0 128 0 177 0
2:3 489 0 0 Both 0
U 100 0 0 0 100 0
1:4 95 0 0 0 95 0
1:5 312 0 0 0 437 0
1:4 3259 0 0 3259 0 0
1:5 110 0 0 0 110 0
1:3 808 0 0 1000 149 0
1:4 77 0 0 77 0 0
U 437 Varisolve, 64
STD, 61 POL
64 498 0
1:4 107 0 0 0 112 0other neurological side effects.35 eThe true incidence of neurological complications fol-
owing sclerotherapy remains unknown and is subject to
ignificant reporting bias. The authors also acknowledge
hat in some of the articles included in this review, impor-
ant details regarding the nature of treatment provision, the
eurological side effects experienced, and cranial or cardiac
maging are omitted from publications, making it difficult
o interpret the relationship between neurological side
Neurological symptoms/disturbances
Cardiac
defectHeadache Visual Speech TIA CVA
0 3 0 0 0 U
0 1 0 0 0 U
3 5 0 0 0 U
0 2 0 0 0 U
0 8 0 0 0 U
0 1 0 0 0 U
0 1 0 0 0 7 PFO
0 0 0 0 0 U
0 2 0 0 0 U
0 0 0 5 0 U
0 4 0 0 0 U
0 2 0 0 0 U
10 20 1 0 0 U
0 7 0 1 0 1 PFO
0 3 0 0 0 U
0 8 0 0 0 U
0 3 0 0 0 U
7% U 0 0 U
1 0 0 0 0 U
2 1 0 0 0 U
0 2 0 0 0 5 PFO
1 0 0 0 0 U
0 14 0 0 0 U
0 2 0 0 0 U
62 6 U 0 0 U 0
0 0 0 0 0 2raine
0
0
0
0
0
0
1
2
1
0
0
0
0
8
0
0
0
0
0
4
1
0
0
0
2ffects and different sclerotherapy regimes.
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1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
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considered acceptable for use by the National Institute for
Health Clinical Excellence, which has provided guidance
for its use.36 However, it is still “off-label,” with the inten-
tion of enhancing efficacy, and the key to success appears to
be appropriate patient selection and caution in certain
patient groups. Obtaining informed consent as well as
adequate posttreatment care with the propensity to avoid,
identify, and treat complications should be routinely insti-
tuted. Sclerotherapy remains a cost-effective way of treating
varicose veins particularly for recurrent veins, patients with
tortuous veins, and those unable to tolerate anesthesia or
sedation, and allows treatment to be performed with min-
imal discomfort, rapid recovery times, and high levels of
patient satisfaction in many cases.37-39 Uniformity in the
reporting standards of studies using sclerotherapy, such as
including details of the type and form of sclerosant used,
the gas mixture, details of the preparation technique, and
the volumes used would be helpful in allowing comparisons
between studies, which at present is difficult due to the
heterogeneity of the reported data. There is also a need for
clinicians to report all major complications to the regula-
tory authorities so that an accurate picture of complication
rates is reported, as there is often a tendency to report only
positive results.40
CONCLUSION
When considering the treatment of varicose veins, a
condition that is commonly perceived as benign, one can
appreciate the enormous tumult related to the major and
potentially fatal neurological complications that have re-
cently been reported with sclerotherapy. Nonetheless, the
current literature highlights their relative infrequency when
considering the millions of sclerotherapy injections that
have been carried out to date. However, precautions
should be exercised particularly in patients with a known
PFO and perhaps those known to suffer from migraine.
AUTHOR CONTRIBUTIONS
Conception and design: AS, TS, AD
Analysis and interpretation: AS, TS, TW
Data collection: AS, TS, TW
Writing the article: AS, TS
Critical revision of the article: TW, AD, AS
Final approval of the article: AS, TS, TW, AD
Statistical analysis: AS, TS, TW
Obtained funding: Not applicable
Overall responsibility: AS, TS, AD
TS and AS contributed equally to this work.
REFERENCES
1. Edwards AG, Baynham S, Lees T, Mitchell DC. Management of vari-
cose veins: a survey of current practice by members of the Vascular
Society of Great Britain and Ireland. Ann R Coll Surg Engl 2009;91:
77-80.
2. Winterborn RJ, Corbett CR. Treatment of varicose veins: the present
and the future–a questionnaire survey. Ann R Coll Surg Engl 2008;90:
561-4.
23. Gohel MS, Epstein DM, Davies AH. Cost-effectiveness of traditional
and endovenous treatments for varicose veins. Br J Surg 2010;97:
1815-23.
4. Wollmann JC. The history of sclerosing foams. Dermatol Surg 2004;
30:694-703; discussion 703.
5. Coleridge Smith P. Sclerotherapy and foam sclerotherapy for varicose
veins. Phlebology 2009;24:260-9.
6. Jia X, Mowatt G, Burr JM, Cassar K, Cook J, Fraser C. Systematic
review of foam sclerotherapy for varicose veins. Br J Surg 2007;94:
925-36.
7. Bush RG,DerrickM,ManjoneyD.Major neurological events following
foam sclerotherapy. Phlebology 2008;23:189-92.
8. ForleeMV, GroudenM,Moore DJ, Shanik G. Stroke after varicose vein
foam injection sclerotherapy. J Vasc Surg 2006;43:162-4.
9. Hahn M, Schulz T, Jünger M. Late stroke after foam sclerotherapy.
VASA 2010;39:108-10.
0. Hanisch F, Müller T, Krivokuca M, Winterholler M. Stroke following
variceal sclerotherapy. Eur J Med Res 2004;9:282-4.
1. Kas A, Begue M, Nifle C, Gil R, Neau JP. [Cerebellar infarction after
sclerotherapy for leg varicosities]. Presse Med 2000;29:1935.
2. Leslie-Mazwi TM, Avery LL, Sims JR. Intra-arterial air thrombogenesis
after cerebral air embolism complicating lower extremity sclerotherapy.
Neurocrit Care 2009;11:247-50.
3. Ma LRW, Pilotelle A, Paraskevas P, Parsi K. Stroke after venous inter-
ventions: three cases of stroke following peripheral venous interven-
tions. Phlebology 2011 March 21;[Epublication ahead of print].
4. Picard C, Deltombe B, Duru C, Godefroy O, Bugnicourt JM. Foam
sclerotherapy: a possible cause of ischaemic stroke? J Neurol Neurosurg,
Psychiatry 2010;81:582-3.
5. Van der Plas JP, Lambers JC, Van Wersch JW, Koehler PJ. Reversible
ischaemic neurological deficit after sclerotherapy of varicose veins.
Lancet 1994;343:428.
6. Peller JA, Gunton RW.Death following injection of sodiummorrhuate.
CMAJ 1951;65:473-5.
7. Drai E, Ferrari E, Bedoucha P, Mihoubi A, Baudouy M, Morand P.
[Sclerosis of varicose veins of the lower limbs causing ischemic cerebral
accident]. Presse Med 1994;23:182.
8. Hartmann K, Harms L, Simon M. Reversible neurological deficit after
foam sclerotherapy. Eur J Vasc Endovasc Surg 2009;38:648-9.
9. Demagny A. Comparative study into the efficacy of a sclerosant product
in the form of liquid or foam in echo-guided sclerosis of the arches of the
long and short saphenous veins. Phlebologie 2002;55:133-7.
0. Kern P, Ramelet AA, Wutschert R, Bounameaux H, Hayoz D. Single-
blind, randomized study comparing chromated glycerin, polidocanol
solution, and polidocanol foam for treatment of telangiectatic leg veins.
Dermatol Surg 2004;30:367-72; discussion 372.
1. Ouvry P, Allaert FA, Desnos P, Hamel-Desnos C. Efficacy of polido-
canol foam versus liquid in sclerotherapy of the great saphenous vein: a
multicentre randomised controlled trial with a 2-year follow-up. Eur J
Vasc Endovasc Surg 2008;36:366-70.
2. Wright D, Gobin JP, Bradbury AW, Coleridge Smith P, Spoelstra H,
Berridge D, et al. Varisolve R polidocanol microfoam compared with
surgery or sclerotherapy in the management of varicose veins in the
presence of trunk vein incompetence: European randomized controlled
trial. Phlebology 2006;21:180-90.
3. Neuhardt D, Morrison N, Rogers C. Emboli detection in the middle
cerebral artery concurrent with treatment of lower extremity superficial
venous insufficiency with foam sclerotherapy: abstracts from the Amer-
ican College of Phlebology 22nd Annual Congress,Marco Island, USA,
6-9 November 2008. Phlebology 2008;24:88.
4. Tessari L. Nouvelle technique d’obtention de la scléro-mousse. Phle-
bologie 2000;53:219.
5. Redondo P, Bastarrika G, Sierra A, Martínez-Cuesta A, Cabrera J.
Efficacy and safety of microfoam sclerotherapy in a patient with Klippel-
Trenaunay syndrome and a patent foramen ovale. Arch Dermatol
2009;145:1147-51.
6. Morrison N, Neuhardt DL. Foam sclerotherapy: cardiac and cerebral
monitoring. Phlebology 2009;24:252-9.7. Gempp E, Blatteau JE. Neurological disorders after repetitive breath-
hold diving. Aviat Space Environ Med 2006;77:971-3.
44
4
4
4
4
4
5
5
5
5
5
5
JOURNAL OF VASCULAR SURGERY
Volume 55, Number 1 Sarvananthan et al 25128. Künzlberger B, Pieck C, Altmeyer P, Stücker M. Migraine ophthal-
mique with reversible scotomas after sclerotherapy with liquid 1%
polidocanol. Dermatol Surg 2006;32:1410-3.
29. Orbach EJ, Petretti AK. The thrombogenic property of foam of a
synthetic anionic detergent (sodium tetradecyl sulfate N.N.R.). Angi-
ology 1950;1:237-43.
30. Hamel-Desnos C, Desnos P, Wollmann JC, Ouvry P, Mako S, Allaert
FA. Evaluation of the efficacy of polidocanol in the form of foam
compared with liquid form in sclerotherapy of the greater saphenous
vein: initial results. Dermatol Surg 2003;29:1170-5; discussion 1175.
31. Guex JJ, Allaert FA, Gillet JL, Chleir F. Immediate and midterm
complications of sclerotherapy: report of a prospective multicenter
registry of 12,173 sclerotherapy sessions. Dermatol Surg 2005;31:
123-8; discussion 128.
32. Gardner WS. Transient hemiplegia following injection of sodium mor-
rhuate. Br Med J 1947;2:613.
33. Gardner WJ, Karnosh LJ, McClure CC Jr, Gardner AK. Residual
function following hemispherectomy for tumour and for infantile hemi-
plegia. Brain 1955;78:487-502.
34. Benigni JP, Ratinahirana H. Polidocanol foam: migraine with aura.
Phlébologie 2003;56:289-91.
35. Bergan J, Pascarella L, Mekenas L. Venous disorders: treatment with
sclerosant foam. J Cardiovasc Surg (Torino) 2006;47:9-18.
36. Bhogal R, Moffat CE. Foam sclerotherapy for bilateral varicose veins:
bilateral vs interval unilateral procedures: Published Abstract from the
Venous Forum 2008. Phlebology 2008;23:201.
37. Bradbury AW, Bate G, Pang K, Darvall KA, Adam DJ. Ultrasound-
guided foam sclerotherapy is a safe and clinically effective treatment for
superficial venous reflux. J Vasc Surg 2010;52:939-45.
38. Cabrera J, Redondo P, Becerra A, Garrido C, Cabrera J Jr, García-
Olmedo MA, et al. Ultrasound-guided injection of polidocanol micro-
foam in the management of venous leg ulcers. Arch Dermatol 2004;
140:667-73.
39. Cabrera J, Cabrera J Jr, Garcia-Olmedo MA. Sclerosants in microfoam.
A new approach in angiology. Int Angiol 2001;20:322-9.
40. Cavezzi A, Frullini A, Ricci S, Tessari A. Treatment of varicose veins by
foam sclerotherapy: two clinical series. Phlebology 2002;17:13-8.
41. Ceulen RP, Sommer A, Vernooy K. Microembolism during foam
sclerotherapy of varicose veins. N Engl J Med 2008;358:1525-6.
42. Chapman-Smith P, Browne A. Prospective five-year study of ultra-
sound-guided foam sclerotherapy in the treatment of great saphenous
vein reflux. Phlebology 2009;24:183-8. S3. Darke SG, Baker SJ. Ultrasound-guided foam sclerotherapy for the
treatment of varicose veins. Br J Surg 2006;93:969-74.
4. Frullini A, Cavezzi A. Sclerosing foam in the treatment of varicose veins
and telangiectases: history and analysis of safety and complications.
Dermatol Surg 2002;28:11-5.
5. Frullini A. New technique in producing sclerosing foam in a disposable
syringe. Dermatol Surg 2000;26:705-6.
6. Gillet JL, Donnet A, Lausecker M, Guedes JM, Guex JJ, Lehmann P.
Pathophysiology of visual disturbances occurring after foam sclerother-
apy. Phlebology 2010;25:261-6.
7. Gillet JL, Guedes JM, Guex JJ, Hamel-Desnos C, Schadeck M,
Lauseker M, et al. Side-effects and complications of foam sclerotherapy
of the great and small saphenous veins: a controlled multicentre pro-
spective study including 1,025 patients. Phlebology 2009;24:131-8.
8. Morrison N, Neuhardt DL, Rogers CR, McEown J, Morrison T,
Johnson E, et al. Comparisons of side effects using air and carbon
dioxide foam for endovenous chemical ablation. J Vasc Surg 2008;47:
830-6.
9. Myers KA, Jolley D, Clough A, Kirwan J. Outcome of ultrasound-
guided sclerotherapy for varicose veins: medium-term results assessed
by ultrasound surveillance. Eur J Vasc Endovasc Surg 2007;33:116-21.
0. Park SW, Yun IJ, Hwang JJ, Lee SA, Kim JS, Chang SH, et al.
Fluoroscopy-guided endovenous foam sclerotherapy using amicrocath-
eter in varicose tributaries followed by endovenous laser treatment of
incompetent saphenous veins: technical feasibility and early results.
Dermatol Surg 2009;35:804-12.
1. Raymond-Martimbeau P. Transient adverse events positively associated
with patent foramen ovale after ultrasound-guided foam sclerotherapy.
Phlebology 2009;24:114-9.
2. Reich-Schupke S, Weyer K, Altmeyer P, Stucker M. Treatment of
varicose tributaries with sclerotherapy with polidocanol 0.5% foam.
VASA 2010;39:169-74.
3. Smith PC. Chronic venous disease treated by ultrasound guided foam
sclerotherapy. Eur J Vasc Endovasc Surg 2006;32:577-83.
4. Tessari L, Cavezzi A, Frullini A. Preliminary experience with a new
sclerosing foam in the treatment of varicose veins. Dermatol Surg
2001;27:58-60.
5. Yamaki T, Nozaki M, Sakurai H, Takeuchi M, Soejima K, Kono T.
Multiple small-dose injections can reduce the passage of sclerosant foam
into deep veins during foam sclerotherapy for varicose veins. Eur J Vasc
Endovasc Surg 2009;37:343-8.ubmitted Feb 22, 2011; accepted May 24, 2011.
